North America Next-Generation Sequencing (NGS) Services Market (2017-2022)
The North America Next-Generation Sequencing (NGS) Services Market was valued at $456.2 Million in 2017 and projected to reach to $1171.7 Million by 2022, representing a compound annual growth rate of CAGR 20.8%. North America's NGS services market is poised for sustained expansion through 2022 and beyond, fueled by declining sequencing costs, increasing clinical adoption, and rising demand for genomic data in oncology, cardiology, and rare disease diagnosis.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America Next-Generation Sequencing (NGS) Services Market Trends and Insights
- This 20.8% compound annual growth rate reflects North America's leadership in genomic research, precision medicine adoption, and advanced diagnostic capabilities.
- North America's dominance is driven by substantial investments in healthcare infrastructure, high prevalence of genetic disorders, and strong demand for personalized treatment approaches across oncology, rare diseases, and reproductive health applications..
Key Market Statistics
- CAGR (2017-2022) CAGR 20.8%
- Market Size, 2017 ~USD 456.2 Million
- Forecast, 2022 ~USD 1171.7 Million
- Geography North America
North America Next-Generation Sequencing (NGS) Services Market Overview
Market Leadership Position :
North America commands the largest share of the global NGS services market, driven by substantial investments in genomic research infrastructure, leading academic institutions, and a concentration of biotechnology companies pioneering sequencing innovations.
Precision Medicine Adoption :
The region leads in integrating NGS into clinical diagnostics and personalized medicine workflows, with healthcare systems increasingly adopting sequencing for cancer genomics, rare disease diagnosis, and pharmacogenomics applications.
Robust Growth Trajectory :
North America's NGS services market is expanding at 20.8% CAGR from 2017–2022, outpacing many global regions and reflecting strong demand from pharmaceutical R&D, clinical laboratories, and research institutions.
Regulatory and Reimbursement Maturity :
Established regulatory frameworks (FDA oversight) and growing insurance reimbursement for NGS-based diagnostics in the U.S. and Canada provide a stable environment for market expansion and service provider growth.
North America Next-Generation Sequencing (NGS) Services Market Dynamics
- The region's advanced healthcare infrastructure, coupled with significant R&D spending by pharmaceutical and biotech firms, positions it as a global innovation hub for sequencing technologies and applications. Key growth drivers include expanding precision medicine initiatives, growing patient awareness of genetic testing, and integration of NGS into routine clinical practice.
- However, market players must navigate regulatory complexities, data privacy concerns, and the need for standardized interpretation protocols.
- Strategic partnerships between service providers, healthcare systems, and research organizations will be critical to capturing emerging opportunities in North America's competitive NGS landscape..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- North America's NGS Services Market is valued at $456.2 million in 2017 and is forecast to reach $1,171.7 million by 2022, representing a 20.8% CAGR.
- North America leads global NGS adoption due to advanced healthcare infrastructure, significant R&D investments, and strong reimbursement frameworks.
- North America's market growth is accelerated by increasing demand for precision medicine, cancer genomics, and non-invasive prenatal testing applications.
- North America's competitive landscape features established players and emerging biotech firms leveraging technological innovation to capture market share.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
North America Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- Pharmaceutical & Biotech Companies : Need comprehensive market data to guide R&D investments, clinical trial design, and companion diagnostic development strategies in North America's rapidly expanding NGS services ecosystem.
- Clinical Laboratory Operators : Require market sizing, competitive benchmarking, and adoption trend analysis to inform service expansion, technology investments, and pricing strategies in the U.S. and Canadian markets.
- Healthcare Systems & Hospital Networks : Seek insights on NGS integration into clinical workflows, reimbursement models, and patient demand forecasts to justify capital expenditures and operational planning for genomic medicine programs.
- Sequencing Technology Vendors : Need regional market intelligence on end-user demand, competitive positioning, and emerging applications to optimize product development, sales strategies, and market penetration in North America.
- Investment & Strategy Consultants : Require detailed market analysis, growth projections, and regional dynamics to advise clients on M&A opportunities, market entry strategies, and portfolio optimization in the NGS services sector.
Key Companies in the North America Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| U.S. | USD 1149.2 Million |
| Canada | USD 22.5 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuations for North America ($456.2M in 2017, $1,171.7M by 2022) with country-level breakdowns for the U.S. and Canada, enabling accurate business planning and investment decisions.
- Competitive Landscape Intelligence : Understand the competitive dynamics specific to North America's NGS services sector, including key players, market consolidation trends, and differentiation strategies in this high-growth region.
- Clinical Adoption & Reimbursement Insights : Access detailed analysis of NGS adoption rates across North American healthcare systems, insurance reimbursement trends, and regulatory pathways that directly impact market penetration and revenue potential.
- Growth Driver Analysis : Identify region-specific growth catalysts including precision medicine initiatives, pharmaceutical R&D spending, academic research funding, and emerging clinical applications driving the 20.8% CAGR.
- Strategic Market Entry & Expansion : Leverage North America-focused market intelligence to develop targeted go-to-market strategies, identify partnership opportunities, and optimize resource allocation for service providers and technology vendors.
Frequently asked questions
What is the market size of NGS Services in North America?
North America's NGS Services Market was valued at $456.2 million in 2017 and is projected to reach $1,171.7 million by 2022.
What is the growth rate of the NGS Services Market in North America?
North America's NGS Services Market is expected to grow at a compound annual growth rate (CAGR) of 20.8% from 2017 to 2022.
What factors are driving NGS Services growth in North America?
North America's NGS market growth is driven by increasing adoption of precision medicine, rising cancer incidence, growing demand for non-invasive prenatal testing, and strong healthcare reimbursement policies.
Which applications dominate the NGS Services Market in North America?
North America's NGS Services Market is dominated by oncology, rare disease diagnosis, reproductive health testing, and infectious disease identification applications.
Who are the key players in North America's NGS Services Market?
North America's NGS Services Market includes major players such as Illumina, Thermo Fisher Scientific, 10x Genomics, and numerous specialized genomic service providers and clinical laboratories.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
